Bajaj Healthcare reported FY26 revenue growth of 12.6% YoY to ₹6,110.3 Mn, with PAT from continuing operations before exceptional items up 35% to ₹545.6 Mn.
The company completed conversion of 2,079,409 warrants into equity shares, raising ₹527 Mn to strengthen its balance sheet and support growth initiatives.
Management highlighted strong 51.6% growth in API exports and progress on 41 DMF filings in Q4, taking cumulative regulatory filings to 110 globally.
The company reversed income from a cancelled technical know-how transfer arrangement in the Middle East due to customer financial commitments and regional instability.